The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell".
The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for Janux Therapeutics, Inc. is $29.00, about 81.3% above its August 5 closing price of $16.00.
Quarterly results
Biopharmaceutical firm's Q2 collaboration revenue was $10.3 million, with net loss narrowing year over year.
Q2 operating expenses fell to $42.0 million from $45.1 million a year earlier.
Company ended Q2 with $970.9 million in cash and short-term investments.
JANX•
